Navigation Links
New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)
Date:5/14/2008

f olmesartan medoxomil in patients with unilateral or bilateral renal artery stenosis, but similar results may be expected.

The prescribing information for BENICAR HCT also includes the following warnings regarding its hydrochlorothiazide component:

BENICAR HCT is not recommended in patients with severe renal impairment and is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs

Fetal/Neonatal Morbidity and Mortality

Thiazides cross the placental barrier and appear in cord blood. There is a risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in adults.

Hepatic Impairment

Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

Hypersensitivity Reaction

Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.

Systemic Lupus Erythematosus

Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus.

Lithium Interaction

Lithium generally should not be given with thiazides.

Adverse Events

In clinical trials, the withdrawal rates due to adverse events (AEs) were similar with BENICAR and BENICAR HCT to placebo: BENICAR (2.4 percent vs 2.7 percent); BENICAR HCT (2.0 percent vs 2.0 percent). The incidence of AEs with BENICAR and BENICAR HCT were similar to placebo. The only AE that occurred in > 1 percent of patients treated with BENICAR and more frequently than placebo was dizziness (3 percent vs 1 percent). AEs reported in > 2 percent of patients taking BENICAR HCT and more frequently than placebo included nausea (3 percent vs 0 percent), hyperuricemia (4 percent vs
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
2. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
3. St. Jude Study Shows How T Cells Machinery Dials Down Autoimmunity
4. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
5. NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
6. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
7. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
8. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
9. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
10. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
11. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Avizia, Inc., a leading provider of cutting-edge ... equity financing round led by NextGen Angels along with ... will be used to continue to fuel the rapidly ... Edward Kennedy , CEO and president of Tollgrade ... Leonard Kurtzman , CFO of newBrandAnalytics, who joined the ...
(Date:8/19/2014)... MALVERN, Pa. , Aug. 19, 2014  SCILEX ... commercialization of late-stage pharmaceutical products for the treatment of ... composed of four members: Dr. Jeff Gudin , ... and Mr. Kip Vought . ... said the expertise of this board would greatly assist ...
(Date:8/19/2014)... Aug. 19, 2014 Luoxis Diagnostics, ... Inc. (NYSE MKT: AMPE), today announced an ... Meeting of the American Academy of Surgical Trauma ... in Philadelphia, Pennsylvania that ... will report results from a recently completed five-year ...
Breaking Medicine Technology:Avizia Closes Funding Round 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 3SCILEX Pharmaceuticals Announces Scientific Advisory Board 4Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3
... Calif., Dec. 21 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... payment from OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI ) ... Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation ... a successful Phase 2 program in patients with advanced prostate ...
... , SAN DIEGO, Dec. 18 LifeVantage Corporation ... Anti-Aging Cream, science-based solutions to oxidative stress, announced today that ... other parties, Zrii, LLC. Under the terms of this agreement, ... William Farley, on the one hand, and the Company and ...
Cached Medicine Technology:Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 2Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 3LifeVantage Announces Settlement of Zrii Litigation 2LifeVantage Announces Settlement of Zrii Litigation 3
(Date:8/20/2014)... Los Angeles, CA (PRWEB) August 20, 2014 ... specialization and a low availability of substitutes typify the ... buyer power score of 3.1 out of 5, indicating ... buyer power suggests buyers and suppliers have an equal ... research analyst Kayley Freshman-Caffrey. , First, few substitutes exist ...
(Date:8/20/2014)... August 20, 2014 First Choice ... emergency rooms in the United States, named Richard Daniels, ... FM 685 facility. , “We are pleased to ... director of our second facility in Pflugerville,” said Dr. ... Emergency Room. , Dr. Daniels received his undergraduate ...
(Date:8/20/2014)... 20, 2014 Kowa Optimed returns after ... to debut the new SL-17 portable slit lamp. , ... white LED source controlled by an illuminated thumb wheel ... SL-17 uses commercially available AAA rechargeable and dry cell ... design requiring batteries designed specifically for the device. The ...
(Date:8/20/2014)... August 20, 2014 This agreement ... of software defined networking, high availability cloud enablement, ... of Resellers, while allowing OPEN-V to sell storageFOUNDRY’s ... pleased to work with OPEN-V on this distribution ... Hows, manager distribution channels at storageFOUNDRY. "Nautilus is ...
(Date:8/19/2014)... 2014 Midtown Dentistry in Houston, Texas, is ... All patients with cavities, or with old fillings that ... that can safely repair and restore teeth. , From now ... materials, all of which are completely amalgam free. Even though ... by the FDA for adults and children over the age ...
Breaking Medicine News(10 mins):Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 4Health News:First Choice Emergency Room Announces Dr. Richard Daniels as Medical Director of the Pflugerville – FM 685 Facility 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2
... Health System set out to reduce energy consumption, they weren,t ... at healthcare facilities. Instead, they,re aiming for a 20 percent ... metric tons of carbon dioxide annually that,s not being released ... the road. The La Crosse, Wis.-based health system is on ...
... a statement by UNITE HERE General President Bruce Raynor:Contrary ... press contact, today,s General Executive Board meeting ended with ... President of UNITE HERE. To be crystal clear: I ... authorized Wilhelm to discuss this issue with me.(Logo: ...
... Only two percent of hospitals nationwide receive Magnet ... Center (ANCC) has announced that Baylor University ... earned re-designation as a Magnet hospital, effective immediately. ... been designated at a Magnet hospital, and merely ...
... Pharmos Corporation (Pink Sheets: PARS) announced today that ... and warrants. At the closing, the Company issued ... an additional 18,000,000 shares of common stock for an ... of the warrants, which have a five-year term, is ...
... 2009 (BRONX, NY) Recurrent and metastatic endometrial ... They have spread to other organs and typically have ... with chemotherapy may not be able to endure more ... of Yeshiva University have shown that a combination of ...
... Exposition Park LOS ANGELES, ... of Dimes premier fundraising event that benefits all babies--those born ... 11,000 walkers are expected at this largest March for Babies ... Park, at the corner of S. Figueroa and 39th St., ...
Cached Medicine News:Health News:Innovative Program Will Help Lead Health System to Energy Independence by 2014 2Health News:Statement From UNITE HERE General President Bruce Raynor on Today's General Executive Board Meeting 2Health News:Baylor Dallas Nationally Recognized for Nursing Excellence 2Health News:Pharmos Completes Private Placement - Raises $1.8 Million 2Health News:Pharmos Completes Private Placement - Raises $1.8 Million 3Health News:New treatment shows promise against recurrent gynecologic cancers 2Health News:Farmers Insurance Joins March of Dimes March for Babies April 25, 2009 2
IBT Reference Laboratory is a national research and specialty clinical lab founded in 1983 that provides a wide range of tests and services in the area of allergy, clinical immunology and molecular b...
Marquette General Health System Reference Laboratory provides a full range of testing including, Chemistry, Hematology, Coagulation, Urinalysis, Microbiology, Cytology, Anatomic Pathology, Flow Cytom...
Headquartered in Burlington, North Carolina, LabCorp has more than 23,500 employees and offers more than 4,400 clinical tests ranging from routine blood analyses to the most sophisticated molecular d...
the LabOne Healthcare Group markets laboratory testing to physicians, patients, managed care companies, self-insured employers, wellness companies and hospitals....
Medicine Products: